Myeloperoxidase (MPO), an inflammatory enzyme derived from white blood cells, identifies vulnerable plaque and is a marker for cardiovascular risk stratification. Understanding the relationship between MPO and vascular inflammation can help identify root cause and risk for cardiometabolic and renal diseases earlier, allowing for mitigation via medication or lifestyle modification. Listen here: http://spr.ly/6040ATnk2
Quest Diagnostics
Medical and Diagnostic Laboratories
Secaucus, NJ 339,404 followers
Working together to create a healthier world, one life at a time.
About us
Quest Diagnostics (NYSE: DGX) empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our 47,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. The company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (AP) services, & interpretive consultation through its medical & scientific staff of about 900 M.D.s & Ph.D.s. The company reported 2020 revenues of $9.44 billion. Quest Diagnostics offers the most extensive clinical testing network in the U.S., with laboratories in most major metropolitan areas, & in Mexico, the UK & India. The company also operates four esoteric laboratories, 40 outpatient AP laboratories, & 160 smaller, rapid-response laboratories. Patients may have specimens collected in any of the company’s approximately 2,250 patient service centers. On a typical workday, testing is performed for about 550,000 patients. Quest Diagnostics empowers healthcare organizations & clinicians with state-of-the-art connectivity solutions. The company is the leading provider of pre-employment drugs-of-abuse screening for employers & risk assessment services for the life insurance industry. It is the world’s 2nd largest provider of clinical trials testing for new pharmaceuticals. More information is available at www.questdiagnostics.com. Language Assistance / Non-Discrimination Notice Asistencia de Idiomas / Aviso de no Discriminación 語言協助 / 不歧視通知 www.QuestDiagnostics.com/home/nondiscrimination
- Website
-
http://www.questdiagnostics.com
External link for Quest Diagnostics
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 10,001+ employees
- Headquarters
- Secaucus, NJ
- Type
- Public Company
- Founded
- 1967
- Specialties
- Diagnostic testing information and services, Clinical testing, cancer diagnostics and anatomic pathology services, Gene-based and other esoteric testing, and Healthcare information technology solutions
Products
![Click here to view Quanum Practice Management]()
Quanum Practice Management
Medical Practice Management Software
Increase the efficiency of your practice with Quanum™ Practice Management. Manage patient appointments, billing & more. Get info today!
Locations
-
Primary
Get directions
500 Plaza Drive
Secaucus, NJ 07094, US
Employees at Quest Diagnostics
Updates
-
“Health-minded consumers want insights from lab testing beyond the annual checkup. Our collaboration with WHOOP is an example of how Quest is broadening access to deep health and wellness insights.” — Richard Adams, SVP, Quest Consumer.
-
During Prostate Cancer Awareness Month, let’s shed light on the innovative IsoPSA testing method for enhanced prostate cancer detection. IsoPSA offers improved accuracy in determining if elevated PSA came from cancer cells by analyzing the structure of the PSA protein. Using advanced testing like IsoPSA, we can revolutionize prostate cancer diagnosis and management, ultimately improving patient outcomes. Together, we can make a significant impact in the fight against prostate cancer. Learn more at: http://spr.ly/6049AB5j9 #ProstateCancerAwareness #IsoPSA
-
Quest Diagnostics reposted this
We're thrilled to announce that Quest Diagnostics is going to begin showing a PSA for the immune assessment tool in its waiting rooms. We'll also be collaborating to improve access to critical diagnostic resources! https://bit.ly/4mRMBrZ
-
Minimal residual disease (MRD) testing is changing how cancer is monitored. On The Results Are In, Dr Thomas Slavin Jr breaks down why this real-time blood-based approach is gaining traction across oncology. Listen in: http://spr.ly/6041Ay8QW #TheResultsAreIn #CancerTreatment #MRDTesting
-
Care starts with Quest’s expansive network of patient-facing services and facilities. In 2024, we scaled our operations to new heights testing ~600,000 patients daily, processing ~217 million test requisitions, and expanding to ~8,000 patient access points nationwide. We’re not just making diagnostics more accessible, we’re working together to create a healthier world, one life at a time. View more key highlights in our 2024 Corporate Responsibility Report: http://spr.ly/6043fNhFV #CorporateResponsibility #CorporateSocialResponsibility
-
-
We’re proud to support the impactful PSA on PSA campaign with Cleveland Diagnostics, raising awareness about the importance of PSA testing in prostate cancer detection and supporting donations to ZERO Prostate Cancer. By joining forces with this initiative, we are committed to promoting early screening, education, and proactive health measures. Together, we can empower individuals to prioritize their well-being and take control of their testing to improve patient outcomes. Join us in supporting the PSA on PSA campaign and making a difference in the fight against prostate cancer. Take the pledge this Prostate Cancer Awareness Month at: https://www.psaonpsa.com/ #ProstateCancerAwareness #PSAonPSA
-
"We are committed to working with the FDA and our research partners to validate the use of Haystack MRD in a variety of solid tumors, building on this first designation for an early-stage colorectal cancer." — Dan Edelstein, Vice President and General Manager, Haystack Oncology. #HealthcareInnovation #MedicalResearch #ColorectalCancer
-
“Our goal for this PGx offering from Quest Diagnostics and Coriell Life Sciences is to help providers more efficiently leverage genetic insights to help guide prescription decisions, and decrease trial-and-error while improving outcomes.” – Steven Keiles, General Manager, US Specialty Genetics and Genomics Services, Quest Diagnostics.